Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 87

1.

Metabolism of Flavone-8-acetic Acid in Mice.

Pham MH, Auzeil N, Regazzetti A, Scherman D, Seguin J, Mignet N, Dauzonne D, Chabot GG.

Anticancer Res. 2016 Aug;36(8):3889-98.

PMID:
27466491
2.

Not flavone-8-acetic acid (FAA) but its murine metabolite 6-OH-FAA exhibits remarkable antivascular activities in vitro.

Pham MH, Dauzonne D, Chabot GG.

Anticancer Drugs. 2016 Jun;27(5):398-406. doi: 10.1097/CAD.0000000000000341.

PMID:
26901071
3.

Antivascular and anti-parasite activities of natural and hemisynthetic flavonoids from New Caledonian Gardenia species (Rubiaceae).

Mai LH, Chabot GG, Grellier P, Quentin L, Dumontet V, Poulain C, Espindola LS, Michel S, Vo HT, Deguin B, Grougnet R.

Eur J Med Chem. 2015 Mar 26;93:93-100. doi: 10.1016/j.ejmech.2015.01.012. Epub 2015 Jan 8.

PMID:
25659770
4.

Bioavailability of polyphenol liposomes: a challenge ahead.

Mignet N, Seguin J, Chabot GG.

Pharmaceutics. 2013 Sep 17;5(3):457-71. doi: 10.3390/pharmaceutics5030457.

5.

Evaluation of Nonradiative Clinical Imaging Techniques for the Longitudinal Assessment of Tumour Growth in Murine CT26 Colon Carcinoma.

Seguin J, Doan BT, Latorre Ossa H, Jugé L, Gennisson JL, Tanter M, Scherman D, Chabot GG, Mignet N.

Int J Mol Imaging. 2013;2013:983534. doi: 10.1155/2013/983534. Epub 2013 Jul 2.

6.

Lipidic spherulites: formulation optimisation by paired optical and cryoelectron microscopy.

Crauste-Manciet S, Larquet E, Khawand K, Bessodes M, Chabot GG, Brossard D, Mignet N.

Eur J Pharm Biopharm. 2013 Nov;85(3 Pt B):1088-94. doi: 10.1016/j.ejpb.2013.02.016. Epub 2013 Mar 21.

PMID:
23523544
7.

Liposomal encapsulation of the natural flavonoid fisetin improves bioavailability and antitumor efficacy.

Seguin J, Brullé L, Boyer R, Lu YM, Ramos Romano M, Touil YS, Scherman D, Bessodes M, Mignet N, Chabot GG.

Int J Pharm. 2013 Feb 28;444(1-2):146-54. doi: 10.1016/j.ijpharm.2013.01.050. Epub 2013 Feb 1.

PMID:
23380621
8.

Synthesis and biological evaluation of enantiomerically pure cyclopropyl analogues of combretastatin A4.

Ty N, Pontikis R, Chabot GG, Devillers E, Quentin L, Bourg S, Florent JC.

Bioorg Med Chem. 2013 Mar 1;21(5):1357-66. doi: 10.1016/j.bmc.2012.11.056. Epub 2012 Dec 21.

PMID:
23369686
9.

Synthesis and in vitro evaluation of potential anticancer activity of mono- and bis-1,2,3-triazole derivatives of bis-alkynes.

Elamari H, Slimi R, Chabot GG, Quentin L, Scherman D, Girard C.

Eur J Med Chem. 2013 Feb;60:360-4. doi: 10.1016/j.ejmech.2012.12.025. Epub 2012 Dec 20.

PMID:
23314049
10.

Colon tumor growth and antivascular treatment in mice: complementary assessment with MR elastography and diffusion-weighted MR imaging.

Jugé L, Doan BT, Seguin J, Albuquerque M, Larrat B, Mignet N, Chabot GG, Scherman D, Paradis V, Vilgrain V, Van Beers BE, Sinkus R.

Radiology. 2012 Aug;264(2):436-44. Epub 2012 Jun 12.

PMID:
22692038
11.

Vascular density and endothelial cell expression of integrin alpha v beta 3 and E-selectin in murine tumours.

Seguin J, Nicolazzi C, Mignet N, Scherman D, Chabot GG.

Tumour Biol. 2012 Oct;33(5):1709-17. doi: 10.1007/s13277-012-0428-x. Epub 2012 Jun 7.

12.

In vitro and in vivo biological evaluation of new 4,5-disubstituted 1,2,3-triazoles as cis-constrained analogs of combretastatin A4.

Mur Blanch N, Chabot GG, Quentin L, Scherman D, Bourg S, Dauzonne D.

Eur J Med Chem. 2012 Aug;54:22-32. doi: 10.1016/j.ejmech.2012.04.017. Epub 2012 May 9.

13.

Nanoemulsion formulation of fisetin improves bioavailability and antitumour activity in mice.

Ragelle H, Crauste-Manciet S, Seguin J, Brossard D, Scherman D, Arnaud P, Chabot GG.

Int J Pharm. 2012 May 10;427(2):452-9. doi: 10.1016/j.ijpharm.2012.02.025. Epub 2012 Feb 24.

14.

Ferrocenyl chalcone difluoridoborates inhibit HIV-1 integrase and display low activity towards cancer and endothelial cells.

Monserrat JP, Al-Safi RI, Tiwari KN, Quentin L, Chabot GG, Vessières A, Jaouen G, Neamati N, Hillard EA.

Bioorg Med Chem Lett. 2011 Oct 15;21(20):6195-7. doi: 10.1016/j.bmcl.2011.07.078. Epub 2011 Aug 5.

PMID:
21889342
15.

Fisetin disposition and metabolism in mice: Identification of geraldol as an active metabolite.

Touil YS, Auzeil N, Boulinguez F, Saighi H, Regazzetti A, Scherman D, Chabot GG.

Biochem Pharmacol. 2011 Dec 1;82(11):1731-9. doi: 10.1016/j.bcp.2011.07.097. Epub 2011 Aug 4.

16.

Synthesis and structure-activity relationships of constrained heterocyclic analogues of combretastatin A4.

Arthuis M, Pontikis R, Chabot GG, Seguin J, Quentin L, Bourg S, Morin-Allory L, Florent JC.

ChemMedChem. 2011 Sep 5;6(9):1693-705. doi: 10.1002/cmdc.201100154. Epub 2011 Jul 5.

PMID:
21732536
17.

Development of a liposomal formulation of the natural flavonoid fisetin.

Mignet N, Seguin J, Ramos Romano M, Brullé L, Touil YS, Scherman D, Bessodes M, Chabot GG.

Int J Pharm. 2012 Feb 14;423(1):69-76. doi: 10.1016/j.ijpharm.2011.04.066. Epub 2011 May 6.

PMID:
21571054
18.

Identification and induction of cytochrome P450s involved in the metabolism of flavone-8-acetic acid in mice.

Pham MH, Rhinn H, Auzeil N, Regazzetti A, Harami DE, Scherman D, Chabot GG.

Drug Metab Lett. 2011 Apr;5(2):73-84.

19.

Domino approach to 2-aroyltrimethoxyindoles as novel heterocyclic combretastatin A4 analogues.

Arthuis M, Pontikis R, Chabot GG, Quentin L, Scherman D, Florent JC.

Eur J Med Chem. 2011 Jan;46(1):95-100. doi: 10.1016/j.ejmech.2010.10.018. Epub 2010 Nov 10.

PMID:
21112130
20.

Improved antiangiogenic and antitumour activity of the combination of the natural flavonoid fisetin and cyclophosphamide in Lewis lung carcinoma-bearing mice.

Touil YS, Seguin J, Scherman D, Chabot GG.

Cancer Chemother Pharmacol. 2011 Aug;68(2):445-55. doi: 10.1007/s00280-010-1505-8. Epub 2010 Nov 11.

21.

Design, synthesis, and biological evaluation of the first podophyllotoxin analogues as potential vascular-disrupting agents.

Labruère R, Gautier B, Testud M, Seguin J, Lenoir C, Desbène-Finck S, Helissey P, Garbay C, Chabot GG, Vidal M, Giorgi-Renault S.

ChemMedChem. 2010 Dec 3;5(12):2016-25. doi: 10.1002/cmdc.201000305.

PMID:
20979080
22.

Synthesis of cytotoxic ferrocenyl flavones via a ferricenium-mediated 1,6-oxidative cyclization.

Monserrat JP, Chabot GG, Hamon L, Quentin L, Scherman D, Jaouen G, Hillard EA.

Chem Commun (Camb). 2010 Jul 28;46(28):5145-7. doi: 10.1039/c0cc01290d. Epub 2010 Jun 16.

PMID:
20556284
23.

Structure-activity relationships of indole compounds derived from combretastatin A4: synthesis and biological screening of 5-phenylpyrrolo[3,4-a]carbazole-1,3-diones as potential antivascular agents.

Ty N, Dupeyre G, Chabot GG, Seguin J, Quentin L, Chiaroni A, Tillequin F, Scherman D, Michel S, Cachet X.

Eur J Med Chem. 2010 Sep;45(9):3726-39. doi: 10.1016/j.ejmech.2010.05.022. Epub 2010 May 15.

PMID:
20538383
24.

Flavonoid-induced morphological modifications of endothelial cells through microtubule stabilization.

Touil YS, Fellous A, Scherman D, Chabot GG.

Nutr Cancer. 2009;61(3):310-21. doi: 10.1080/01635580802521346.

25.

Synthesis and biological evaluation of new disubstituted analogues of 6-methoxy-3-(3',4',5'-trimethoxybenzoyl)-1H-indole (BPR0L075), as potential antivascular agents.

Ty N, Dupeyre G, Chabot GG, Seguin J, Tillequin F, Scherman D, Michel S, Cachet X.

Bioorg Med Chem. 2008 Aug 1;16(15):7494-503. doi: 10.1016/j.bmc.2008.06.002. Epub 2008 Jun 7.

PMID:
18583138
26.

Importance of dose-schedule of 5-aza-2'-deoxycytidine for epigenetic therapy of cancer.

Lemaire M, Chabot GG, Raynal NJ, Momparler LF, Hurtubise A, Bernstein ML, Momparler RL.

BMC Cancer. 2008 May 2;8:128. doi: 10.1186/1471-2407-8-128.

27.

Characterization of monohydroxylated derivatives of the anticancer agent flavone-8-acetic acid by liquid chromatography with on-line UV and mass spectrometry.

Pham MH, Menet MC, Dugay A, Regazzetti A, Dauzonne D, Auzeil N, Scherman D, Chabot GG.

Rapid Commun Mass Spectrom. 2007;21(20):3373-86.

PMID:
17891752
28.

Identification of new flavone-8-acetic acid metabolites using mouse microsomes and comparison with human microsomes.

Pham MH, Auzeil N, Regazzetti A, Dauzonne D, Dugay A, Menet MC, Scherman D, Chabot GG.

Drug Metab Dispos. 2007 Nov;35(11):2023-34. Epub 2007 Jul 30.

PMID:
17664249
29.

In vivo electrochemical detection of nitric oxide in tumor-bearing mice.

Griveau S, Dumézy C, Séguin J, Chabot GG, Scherman D, Bedioui F.

Anal Chem. 2007 Feb 1;79(3):1030-3.

PMID:
17263331
30.

Synthesis and biological evaluation of (3,4,5-trimethoxyphenyl)indol-3-ylmethane derivatives as potential antivascular agents.

Dupeyre G, Chabot GG, Thoret S, Cachet X, Seguin J, Guénard D, Tillequin F, Scherman D, Koch M, Michel S.

Bioorg Med Chem. 2006 Jul 1;14(13):4410-26. Epub 2006 Mar 10.

PMID:
16529936
31.

Regulation of CYP26A1 expression by selective RAR and RXR agonists in human NB4 promyelocytic leukemia cells.

Idres N, Marill J, Chabot GG.

Biochem Pharmacol. 2005 Jun 1;69(11):1595-601. Epub 2005 Apr 2.

PMID:
15896339
32.

Retinoic acid metabolism and mechanism of action: a review.

Marill J, Idres N, Capron CC, Nguyen E, Chabot GG.

Curr Drug Metab. 2003 Feb;4(1):1-10. Review.

PMID:
12570742
33.

Activation of retinoic acid receptor-dependent transcription by all-trans-retinoic acid metabolites and isomers.

Idres N, Marill J, Flexor MA, Chabot GG.

J Biol Chem. 2002 Aug 30;277(35):31491-8. Epub 2002 Jun 17.

34.

Human cytochrome P450s involved in the metabolism of 9-cis- and 13-cis-retinoic acids.

Marill J, Capron CC, Idres N, Chabot GG.

Biochem Pharmacol. 2002 Mar 1;63(5):933-43.

PMID:
11911845
35.

Granulocytic differentiation of human NB4 promyelocytic leukemia cells induced by all-trans retinoic acid metabolites.

Idres N, Benoît G, Flexor MA, Lanotte M, Chabot GG.

Cancer Res. 2001 Jan 15;61(2):700-5.

36.

Identification of human cytochrome P450s involved in the formation of all-trans-retinoic acid principal metabolites.

Marill J, Cresteil T, Lanotte M, Chabot GG.

Mol Pharmacol. 2000 Dec;58(6):1341-8.

PMID:
11093772
37.

[Irinotecan pharmacokinetics].

Chabot GG, Robert J, Lokiec F, Canal P.

Bull Cancer. 1998 Dec;Spec No:11-20. Review. French.

PMID:
9932079
38.

Clinical pharmacokinetics of irinotecan.

Chabot GG.

Clin Pharmacokinet. 1997 Oct;33(4):245-59. Review.

PMID:
9342501
39.

Expression and inducibility of cytochrome P450 3A9 (CYP3A9) and other members of the CYP3A subfamily in rat liver.

Mahnke A, Strotkamp D, Roos PH, Hanstein WG, Chabot GG, Nef P.

Arch Biochem Biophys. 1997 Jan 1;337(1):62-8.

PMID:
8990268
40.

Preclinical antitumor activity and pharmacokinetics of irinotecan (CPT-11) in tumor-bearing mice.

Bissery MC, Vrignaud P, Lavelle F, Chabot GG.

Ann N Y Acad Sci. 1996 Dec 13;803:173-80. Review. No abstract available.

PMID:
8993510
41.

Clinical pharmacology and pharmacodynamics of irinotecan. A review.

Chabot GG.

Ann N Y Acad Sci. 1996 Dec 13;803:164-72. Review. No abstract available.

PMID:
8993509
42.

Etoposide bioavailability after oral administration of the prodrug etoposide phosphate in cancer patients during a phase I study.

Chabot GG, Armand JP, Terret C, de Forni M, Abigerges D, Winograd B, Igwemezie L, Schacter L, Kaul S, Ropers J, Bonnay M.

J Clin Oncol. 1996 Jul;14(7):2020-30.

PMID:
8683232
43.

In vivo induction of cytochrome P450 CYP3A expression in rat leukocytes using various inducers.

Mahnke A, Roos PH, Hanstein WG, Chabot GG.

Biochem Pharmacol. 1996 Jun 14;51(11):1579-82.

PMID:
8630100
44.

Experimental antitumor activity and pharmacokinetics of the camptothecin analog irinotecan (CPT-11) in mice.

Bissery MC, Vrignaud P, Lavelle F, Chabot GG.

Anticancer Drugs. 1996 Jun;7(4):437-60.

PMID:
8826613
45.

Phase I and pharmacology study of intoplicine (RP 60475; NSC 645008), novel topoisomerase I and II inhibitor, in cancer patients.

Abigerges D, Armand JP, Chabot GG, Bruno R, Bissery MC, Bayssas M, Klink-Alakl M, Clavel M, Catimel G.

Anticancer Drugs. 1996 Feb;7(2):166-74.

PMID:
8740721
46.

Main drug-metabolizing enzyme systems in human non-Hodgkin's lymphomas sensitive or resistant to chemotherapy.

Ribrag V, Massaad L, Janot F, Morizet J, Gouyette A, Chabot GG.

Leuk Lymphoma. 1995 Jul;18(3-4):303-10.

PMID:
8535197
47.

Population pharmacokinetics and pharmacodynamics of irinotecan (CPT-11) and active metabolite SN-38 during phase I trials.

Chabot GG, Abigerges D, Catimel G, Culine S, de Forni M, Extra JM, Mahjoubi M, Hérait P, Armand JP, Bugat R, et al.

Ann Oncol. 1995 Feb;6(2):141-51.

PMID:
7786822
48.

Phase I and pharmacokinetic study of irinotecan (CPT-11) administered daily for three consecutive days every three weeks in patients with advanced solid tumors.

Catimel G, Chabot GG, Guastalla JP, Dumortier A, Cote C, Engel C, Gouyette A, Mathieu-Boué A, Mahjoubi M, Clavel M.

Ann Oncol. 1995 Feb;6(2):133-40.

PMID:
7786821
49.

Phase I and pharmacology study of flavone acetic acid administered two or three times weekly without alkalinization.

de Forni M, Chabot GG, Armand JP, Gouyette A, Klink-Alak M, Recondo G.

Cancer Chemother Pharmacol. 1995;35(3):219-24.

PMID:
7805180
50.

Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patients.

Abigerges D, Chabot GG, Armand JP, Hérait P, Gouyette A, Gandia D.

J Clin Oncol. 1995 Jan;13(1):210-21.

PMID:
7799022

Supplemental Content

Loading ...
Support Center